Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of neurocognitive impairment at 3 years after a first episode non-affective psychosis.
Ayesa-Arriola R, Pérez-Iglesias R, Rodríguez-Sánchez JM, Pardo-García G, Tabares-Seisdedos R, Ayuso-Mateos JL, Vázquez-Barquero JL, Crespo-Facorro B. Ayesa-Arriola R, et al. Among authors: vazquez barquero jl. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:23-8. doi: 10.1016/j.pnpbp.2012.11.012. Epub 2012 Dec 7. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23228461
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, Ramirez-Bonilla M, Pelayo-Terán JM, Vázquez-Barquero JL. Crespo-Facorro B, et al. J Psychiatr Res. 2011 Jun;45(6):763-9. doi: 10.1016/j.jpsychires.2010.11.002. Epub 2010 Nov 23. J Psychiatr Res. 2011. PMID: 21106207 Clinical Trial.
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ramirez-Bonilla M, Martínez-Garcia O, Pardo-Garcia G, Caseiro O, Pelayo-Terán JM, Vázquez-Barquero JL. Crespo-Facorro B, et al. J Psychopharmacol. 2011 Jun;25(6):744-54. doi: 10.1177/0269881110388332. Epub 2011 Feb 3. J Psychopharmacol. 2011. PMID: 21292922 Clinical Trial.
Homocysteine and cognition in first-episode psychosis patients.
Ayesa-Arriola R, Pérez-Iglesias R, Rodríguez-Sánchez JM, Mata I, Gómez-Ruiz E, García-Unzueta M, Martínez-García O, Tabares-Seisdedos R, Vázquez-Barquero JL, Crespo-Facorro B. Ayesa-Arriola R, et al. Eur Arch Psychiatry Clin Neurosci. 2012 Oct;262(7):557-64. doi: 10.1007/s00406-012-0302-2. Epub 2012 Mar 2. Eur Arch Psychiatry Clin Neurosci. 2012. PMID: 22382435
1-year follow-up study of cognitive function in first-episode non-affective psychosis.
Rodríguez-Sánchez JM, Pérez-Iglesias R, González-Blanch C, Pelayo-Terán JM, Mata I, Martínez O, Sánchez-Cubillo I, Vázquez-Barquero JL, Crespo-Facorro B. Rodríguez-Sánchez JM, et al. Schizophr Res. 2008 Sep;104(1-3):165-74. doi: 10.1016/j.schres.2008.05.020. Epub 2008 Jul 16. Schizophr Res. 2008. PMID: 18635340
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL. Crespo-Facorro B, et al. J Psychiatr Res. 2007 Oct;41(8):659-66. doi: 10.1016/j.jpsychires.2006.05.002. Epub 2006 Jun 23. J Psychiatr Res. 2007. PMID: 16797591 Clinical Trial.
204 results